Photobiomodulation therapy prevents dysgeusia chemotherapy induced in breast cancer women treated with doxorubicin plus cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical trial

[1] Gadisa DA(2020)Toxicity profile of doxorubicin-cyclophosphamide and doxorubicin-cyclophosphamide followed by paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: a prospective cohort study J Oncol Pharm Pract 26 1912-1920

[2] Assefa M(2011)International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy J Natl Cancer Inst Monogr 43 147-151

[3] Wang SH(2020)Analysis of the doxorubicin and doxorubicinol in the plasma of breast cancer patients for monitoring the toxicity of doxorubicin Drug Des Devel Ther 25 3469-3475

[4] Yimer G(2020)Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions Exp Neurol 32 113-118

[5] Berruti A(2020)Modifications of taste sensitivity in cancer patients: a method for the evaluations of dysgeusia Support Care Cancer 28 1173-1181

[6] Generali D(2018)Taste and smell perception and quality of life during and after systemic therapy for breast cancer Breast Cancer Res Treat 170 27-34

[7] Kaufmann M(2017)Differences in dietary in take during chemotherapy in breast cancer patients compared to women without cancer Support Care Cancer 25 2581-2591

[8] Puztai L(2015)Lasers in dentistry: guideline for clinical practice Willey Beckwell 49 27-33

[9] Curigliano G(2019)Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities: a systematic review Oral Oncol 93 21-28

[10] Harahap Y(2010)Use of 660 nm diode laser in the prevention and treatment of human oral mucositis induced by radiotherapy and chemotherapy Photomed Laser Surg 28 233-237

[1] Gadisa DA(2020)Toxicity profile of doxorubicin-cyclophosphamide and doxorubicin-cyclophosphamide followed by paclitaxel regimen and its associated factors among women with breast cancer in Ethiopia: a prospective cohort study J Oncol Pharm Pract 26 1912-1920

[2] Assefa M(2011)International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy J Natl Cancer Inst Monogr 43 147-151

[3] Wang SH(2020)Analysis of the doxorubicin and doxorubicinol in the plasma of breast cancer patients for monitoring the toxicity of doxorubicin Drug Des Devel Ther 25 3469-3475

[4] Yimer G(2020)Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions Exp Neurol 32 113-118

[5] Berruti A(2020)Modifications of taste sensitivity in cancer patients: a method for the evaluations of dysgeusia Support Care Cancer 28 1173-1181

[6] Generali D(2018)Taste and smell perception and quality of life during and after systemic therapy for breast cancer Breast Cancer Res Treat 170 27-34

[7] Kaufmann M(2017)Differences in dietary in take during chemotherapy in breast cancer patients compared to women without cancer Support Care Cancer 25 2581-2591

[8] Puztai L(2015)Lasers in dentistry: guideline for clinical practice Willey Beckwell 49 27-33

[9] Curigliano G(2019)Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities: a systematic review Oral Oncol 93 21-28

[10] Harahap Y(2010)Use of 660 nm diode laser in the prevention and treatment of human oral mucositis induced by radiotherapy and chemotherapy Photomed Laser Surg 28 233-237